The United States Patent and Trademark Office (USPTO)’s withdrawal of its proposed terminal disclaimer rule is seen as a ...

Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat ...

The proposed pertuzumab biosimilar QL1209 demonstrated equivalent efficacy and safety to reference pertuzumab (Perjeta) in ...

A French real-world study found that the adalimumab biosimilar SB5 was effective in treating rheumatic or gastrointestinal ...

Number 5: Regulatory policies influence the availability of affordable biosimilars, with varying impacts across different jurisdictions. Number 4: The study findings demonstrate that the aflibercept ...